IPSC Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 15.67%, SMA50 33.22%, SMA200 169.16%). The stock’s 14-day RSI is 62.02 (firm momentum), while the ATR of 0.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.34% below its high and over 555.35% above its low. Average 10-day trading volume of 828.88 thousand shares is below the 3-month average of 1.74 million, indicating normal recent market interest.

Century Therapeutics, Inc. generated EPS of -$0.31 over the past year. Five-year average earnings growth is 18.46%. Wall Street analysts project EPS growth of 30.38% annually over the next five years. The latest quarter delivered EPS of -$0.32. The next quarter is forecast at -$0.29. Next year's EPS is expected at -$6.40. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 4 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $2.00. The high target offers 212.5% upside. The low target suggests -10.71% downside. The mean target is $4.00. This offers 78.57% upside. Century Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 13, 2025, missed forecasts by -17.95%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -24.0% in August 08, 2024.

Century Therapeutics, Inc. has 86.16 million shares outstanding. The public float is 45.36 million shares, elevated short interest at 2.32% of float. This equals 1.34 million shares. The short ratio is 1.33 days. Institutional investors hold 57.21% of the float. Insiders own 26.69%. BAYER AKTIENGESELLSCHAFT holds 12.68 million shares, Versant Vantage II GP-GP, LLC has 11.82 million shares and Versant Venture Capital VI, L.P. has 11.82 million shares. Over the past six months, insider transactions show net selling. They sold 40.61 thousand shares across 9 transactions.

Century Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.26. This means the shares are trading below this model’s fair value.

Century Therapeutics, Inc. (NASDAQ:IPSC) closed at $2.24 USD, gaining $0.06 (2.75%) from the previous close of $2.18. The stock is currently mid-range between its 52-week high and low $0.34 and $2.71. With a market capitalization of about $195.79 million, Century Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.76). Key stats such as the average daily volume over the past year has been around 1.77 million shares, in line with its 52-week average. Headquartered in Philadelphia, PA, Century Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Brent Pfeiffenberger, the company employs approximately 140 people and listed since June 18, 2021. Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.

Century Therapeutics, Inc. trades at a P/E ratio of -7.35, slightly below the S&P 500 average, with a price-to-sales ratio of 1.74 and a price-to-book ratio of 1.1 suggesting the stock is closer to book value. The P/FCF stands at -1.75, also below market averages.

Our AI price prediction model suggests that Century Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.89%, with price expected at $2.22 by March 12, 2026, within a range of $1.91 to $2.54 3-Month Outlook: Projected rise of 237.95%, reaching $7.57 by May 27, 2026, with a range of $7.52 to $7.65. 1-Year Outlook: Projected gain of 1011.61%, with price at $24.90 by February 26, 2027, within a range of $23.98 to $32.25.

Century Therapeutics, Inc. (NASDAQ:IPSC) shares are up 93.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Century Therapeutics, Inc. trading at a premium to the broader market with a P/E of -7.35. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $13.48, suggesting 501.79% upside. Our AI forecast model points to short-term weakness (-0.89% over two weeks), a medium-term rise (237.95% over three months), and a longer-term gain (1011.61% over one year), with expected trading ranges indicating moderate volatility.